{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-103780","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.937940+00:00","generated_at":"2026-05-17T01:25:31.130852+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Incannex updates on Phase 2 results for IHL-42X and PSX-001; ATM shares unchanged since Aug 2025","bullets":["IHL-42X Phase 2 OSA trial showed up to 83% reduction in AHI; 57.6% of participants reported improvement (78.6% low dose).","PSX-001 Phase 2 GAD trial met primary endpoint HAM-A and multiple secondary measures with sustained relief over 11 weeks, no SAEs.","ATM facility not utilized since Aug 28, 2025; total shares outstanding unchanged at 347,705,507.","Company prioritizing FDA engagement for pivotal development of IHL-42X and PSX-001, and exploring partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-103780","json":"https://secwatch.observer/filing/0001213900-25-103780.json","markdown":"https://secwatch.observer/filing/0001213900-25-103780.md","text":"https://secwatch.observer/filing/0001213900-25-103780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025103780/0001213900-25-103780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025103780/ea0262765-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:25:31.130852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}